AVPR2 and heart failure: Nonetheless, recent clinical guidelines on the diagnosis and the treatment of heart failure issued by the European Society of Cardiology indicate that tolvaptan, a selective V2R antagonist, can be considered for the treatment of heart failure patients with hyponatremia [272].